Interstitial lung abnormalities are more prevalent in individuals with PRISm, and those with PRISm and ILAs have higher all-cause mortality.

The current state of treatment for geographic atrophy is marked by two approved therapies that slow GA progression: pegcetacoplan, or Syfovre, from Apellis Pharmaceuticals and avacincaptad pegol ...

Prism Johnson Ltd., incorporated in the year 1992, is a Mid Cap company (having a market cap of Rs 6,816.45 Crore) operating in Cement sector. Prism Johnson Ltd. key Products/Revenue Segments include ...